<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930055</url>
  </required_header>
  <id_info>
    <org_study_id>CTO-IUSCCC-0759</org_study_id>
    <nct_id>NCT04930055</nct_id>
  </id_info>
  <brief_title>Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)</brief_title>
  <official_title>Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of this study are to assess vaccine performance (safety and efficacy) and to&#xD;
      collect serum and peripheral blood mononuclear cells (PBMCs) pre and post-vaccination to&#xD;
      assess immune and other response parameters following immunization in cancer patients&#xD;
      receiving either the Pfizer (BTN162b2) (6), Moderna (mRNA-1273) (7), or the Janssen&#xD;
      (Ad26.COV2.S) (8) vaccines under the FDA Emergency Use Authorization (as per the decision of&#xD;
      their treating physician judgment and standard of care)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">August 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 11, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event Collection</measure>
    <time_frame>from date of vaccination until 2 months after full vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19 infection</measure>
    <time_frame>from date of vaccination until 6 months after full vaccination</time_frame>
  </secondary_outcome>
  <number_of_groups>12</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients with solid tumors receiving courses of cytotoxic therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Patients with hematological cancers receiving courses of cytotoxic chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Patients with solid tumors receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>Patients with hematologic cancers receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <description>Patients receiving immune checkpoint inhibitors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <description>Patients who underwent allogeneic stem cell transplant within 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <description>Patients who underwent cellular therapy, including CAR-T cells or T cells with engineered TCRs within 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8</arm_group_label>
    <description>Patients in remission who have received cellular therapy more than 12 months in the past, including allogeneic, autologous or engineered cellular approaches</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9</arm_group_label>
    <description>Patients with cancer in remission for at least 2 years not receiving active cytotoxic cancer chemotherapy (hormonal therapy is permitted).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10</arm_group_label>
    <description>Patients who have undergone allogenic bone marrow transplant and are currently receiving immunosuppressants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 11</arm_group_label>
    <description>Patients who have undergone allogenic bone marrow transplant who are not currently receiving immunosuppressants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 12</arm_group_label>
    <description>Patients who have a cancer diagnosis but do not fall into group 1-11</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 Vaccination</intervention_name>
    <description>Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 10</arm_group_label>
    <arm_group_label>Group 11</arm_group_label>
    <arm_group_label>Group 12</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_label>Group 9</arm_group_label>
    <other_name>Moderna (mRNA-1273)</other_name>
    <other_name>Pfizer (BTN162b2)</other_name>
    <other_name>Janssen (Ad26.COV2.S)</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum Collection at 1 and 3 months after Dose 2 for Moderna/Pfizer vaccinations and 1 and 3&#xD;
      months after Dose 1 for Janssen vaccinations.&#xD;
&#xD;
      PBMC Collection at Dose 2,+1 month , +3 months, +6 months and +12 months after their Dose 2&#xD;
      for Pfizer/Moderna vaccinations. Collection at +1 month,+3 months,, +6 months and +12 months&#xD;
      after their Dose 1 for Janssen vaccinations&#xD;
&#xD;
      Serum and peripheral blood mononuclear cells (PBMC) will be cryopreserved for molecular and&#xD;
      immunologic studies that can include, but are not limited, to antibody titers, cytokines and&#xD;
      chemokines, immune cell subsets and T cell and B cell analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a current or previous cancer diagnosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to provide written informed consent and HIPAA authorization&#xD;
&#xD;
          2. Patients deemed eligible and willing to receive a COVID-19 vaccine by treating&#xD;
             physician per standard of care.&#xD;
&#xD;
          3. Subjects must be â‰¥ 18 years old at the time of consent.&#xD;
&#xD;
          4. Diagnosis of cancer and fall into one of the groups below:&#xD;
&#xD;
               1. Group 1: Patients with solid tumors receiving courses of cytotoxic therapy.&#xD;
&#xD;
               2. Group 2: Patients with hematological cancers receiving courses of cytotoxic&#xD;
                  chemotherapy.&#xD;
&#xD;
               3. Group 3: Patients with solid tumors receiving tyrosine kinase inhibitors (TKIs)&#xD;
                  or other targeted therapies, but not cytotoxic regimens within 3 months.&#xD;
&#xD;
               4. Group 4: Patients with hematologic cancers receiving TKIs or other targeted&#xD;
                  therapies, but not cytotoxic regimens within 3 months.&#xD;
&#xD;
               5. Group 5: Patients receiving immune checkpoint inhibitors.&#xD;
&#xD;
               6. Group 6: Patients who underwent allogeneic stem cell transplant within 12 months.&#xD;
&#xD;
               7. Group 7: Patients who underwent cellular therapy, including Chimeric antigen&#xD;
                  receptor t-cells (CAR-T) cells or t-cells with engineered t-cell receptors (TCRs)&#xD;
                  within 12 months.&#xD;
&#xD;
               8. Group 8: Patients in remission who have received cellular therapy more than 12&#xD;
                  months in the past, including allogeneic, autologous or engineered cellular&#xD;
                  approaches.&#xD;
&#xD;
               9. Group 9: Patients with cancer in remission for at least 2 years not receiving&#xD;
                  active cytotoxic cancer chemotherapy (hormonal therapy is permitted).&#xD;
&#xD;
              10. Group 10: Patients who have undergone allogenic bone marrow transplant and are&#xD;
                  currently receiving immunosuppressants&#xD;
&#xD;
              11. Group 11: Patients who have undergone allogenic bone marrow transplant who are&#xD;
                  not currently receiving immunosuppressants&#xD;
&#xD;
              12. Group 12: Patients who have a cancer diagnosis but do not fall into group 1-11&#xD;
&#xD;
        3. Estimated survival of 8 weeks or more following enrollment on the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             COVID-19 infection or influenza-like-illness. If subjects have previously tested&#xD;
             positive for COVID-19 infection, they are eligible to participate in this study after&#xD;
             90 days&#xD;
&#xD;
             2. Unwilling or unable to follow protocol requirements.&#xD;
&#xD;
             3. Subjects who have received any prior COVID-19 vaccination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Utpal Dave, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Millicent MacGregor, RN</last_name>
    <phone>317-274-5288</phone>
    <email>milmacgr@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Spittler, RN</last_name>
    <phone>(317) 274-0771</phone>
    <email>ajspittl@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IU Health Joe and Shelly Schwarz Cancer Center</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Spittler, RN</last_name>
      <phone>317-274-0771</phone>
      <email>ajspittl@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Utpal Dave, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Comprehensive Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Millicent MacGregor, RN</last_name>
      <email>milmacgr@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Utpal Dave, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Utpal P. DavÃ©</investigator_full_name>
    <investigator_title>Associate Professor Department of Medicine Division of Hematology/Oncology</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Pfizer</keyword>
  <keyword>Moderna</keyword>
  <keyword>Janssen</keyword>
  <keyword>COVID</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

